Radioembolization for previously treated liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment called yttrium-90 carbon microsphere radioembolization for people with liver cancer that has been previously treated. Tiny radioactive beads are delivered directly to the tumor through the blood vessels to destroy cancer cells from inside. This may be an option if your liver cancer has not spread beyond the liver and you can tolerate the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and weigh more than 66 pounds (30 kg).
- You have been diagnosed with liver cancer (hepatocellular carcinoma) by imaging or biopsy.
- You have already received treatments like TACE or HAIC for your liver cancer.
- Your liver function is relatively good (Child-Pugh score 7 or lower) and you are able to care for yourself (ECOG performance status 0 or 1).
- Your cancer is only in the liver, not spread to other organs.
- You have at least one tumor that can be measured on scans.
- Your blood counts, liver and kidney function, and clotting are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining radiation therapy (radioembolization) with surgery to remove part of the liver for people with a single large liver tumor (over 8 cm) that hasn't spread. The goal is to see if this approach can treat the tumor effectively.
This trial tests a targeted radiation treatment (radioembolization) for liver cancer that has grown into the main vein (portal vein) but is still limited to one lobe of the liver. It is for people who have not received any prior cancer treatment and whose liver function is still fairly good.
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
This Phase 2 trial tests TheraSphere® (a Y-90 radiation treatment delivered to the liver) combined with standard systemic therapy in people with high-risk hepatocellular carcinoma (HCC). It aims to shrink tumors and improve outcomes for people whose liver cancer is at higher risk to worsen.
This trial tests a treatment called Y-90 radioembolization (SIRT) for people with liver cancer that is too large to be removed surgically. The treatment delivers tiny radioactive beads directly to the tumor through the liver's blood supply, which may shrink the tumor and improve outcomes.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.